Literature DB >> 7949167

Origin of human mast cells: development from transplanted hematopoietic stem cells after allogeneic bone marrow transplantation.

M Födinger1, G Fritsch, K Winkler, W Emminger, G Mitterbauer, H Gadner, P Valent, C Mannhalter.   

Abstract

Although mast cells are hematopoietic cells, little is known about the origin of their precursors in vivo. In this study, the origin (donor v recipient genotype) of human mast cells (MCs) was analyzed in a patient who underwent allogeneic bone marrow transplantation (BMT). The patient presented with secondary acute myeloid leukemia (French-American-British classification, M2) arising from refractory anemia with excess of blast cells and bone marrow (BM) mastocytosis. Transplantation was performed in chemotherapy-induced complete remission. On days 88, 126, 198, and 494 after BMT, mast cells were enriched to homogeneity from bone marrow mononuclear cells (BM MNCs) by cell sorting for CD117+/CD34- cells. Purified mast cell populations were CD117(c-kit)+ (> 95%), CD34- (< 1%), CD3- (< 1%), CD14- (< 1%), and virtually free of contaminating cells as assessed by Giemsa staining. The genotype of MCs was analyzed after amplification by polymerase chain reaction (PCR) of a variable number tandem repeat (VNTR) region within intron 40 of the von Willebrand factor (vWF) gene. Unexpectedly, on days 88 and 126 after BMT, sorted MCs displayed recipient genotype as shown by vWF.VNTR-PCR. However, on days 198 and 494, PCR analysis showed a switch to donor genotype in isolated mast cells. Peripheral blood (PB) and BM MNC as well as highly enriched (sorted) CD3+ T cells (PB, BM), CD4+ helper T cells (PB), CD8+ T cells (PB), CD19+ B cells (PB), CD14+ monocytes (PB, BM), and CD34+ precursor cells (BM) showed donor genotype throughout the observation period. Together, these results provide evidence that human MCs developed in vivo from transplanted hematopoietic stem cells. Engraftment and in vivo differentiation of MCs from early hematopoietic progenitor cells may be a prolonged process.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7949167

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  22 in total

1.  Optimization of an Acridine Orange-bisbenzimide procedure for the detection of apoptosis-associated fluorescence colour changes in etoposide-treated cell cultures.

Authors:  Nadia L Landex; Lars Kayser
Journal:  J Mol Histol       Date:  2004-02       Impact factor: 2.611

2.  Hematopoietic stem-cell transplantation for advanced systemic mastocytosis.

Authors:  Celalettin Ustun; Andreas Reiter; Bart L Scott; Ryotaro Nakamura; Gandhi Damaj; Sebastian Kreil; Ryan Shanley; William J Hogan; Miguel-Angel Perales; Tsiporah Shore; Herrad Baurmann; Robert Stuart; Bernd Gruhn; Michael Doubek; Jack W Hsu; Eleni Tholouli; Tanja Gromke; Lucy A Godley; Livio Pagano; Andrew Gilman; Eva Maria Wagner; Tor Shwayder; Martin Bornhäuser; Esperanza B Papadopoulos; Alexandra Böhm; Gregory Vercellotti; Maria Teresa Van Lint; Christoph Schmid; Werner Rabitsch; Vinod Pullarkat; Faezeh Legrand; Ibrahim Yakoub-Agha; Wael Saber; John Barrett; Olivier Hermine; Hans Hagglund; Wolfgang R Sperr; Uday Popat; Edwin P Alyea; Steven Devine; H Joachim Deeg; Daniel Weisdorf; Cem Akin; Peter Valent
Journal:  J Clin Oncol       Date:  2014-08-25       Impact factor: 44.544

Review 3.  Myeloid cells in atherosclerosis: initiators and decision shapers.

Authors:  Oliver Soehnlein; Christian Weber
Journal:  Semin Immunopathol       Date:  2009-02-24       Impact factor: 9.623

4.  Flow cytometric analysis of mast cells from normal and pathological human bone marrow samples: identification and enumeration.

Authors:  A Orfao; L Escribano; J Villarrubia; J L Velasco; C Cerveró; J Ciudad; J L Navarro; J F San Miguel
Journal:  Am J Pathol       Date:  1996-11       Impact factor: 4.307

5.  Phagocytic and tumor necrosis factor alpha response of human mast cells following exposure to gram-negative and gram-positive bacteria.

Authors:  M Arock; E Ross; R Lai-Kuen; G Averlant; Z Gao; S N Abraham
Journal:  Infect Immun       Date:  1998-12       Impact factor: 3.441

Review 6.  Deciphering the differentiation trajectory from hematopoietic stem cells to mast cells.

Authors:  Jennine Grootens; Johanna S Ungerstedt; Gunnar Nilsson; Joakim S Dahlin
Journal:  Blood Adv       Date:  2018-09-11

Review 7.  Midostaurin: a magic bullet that blocks mast cell expansion and activation.

Authors:  P Valent; C Akin; K Hartmann; T I George; K Sotlar; B Peter; K V Gleixner; K Blatt; W R Sperr; P W Manley; O Hermine; H C Kluin-Nelemans; M Arock; H-P Horny; A Reiter; J Gotlib
Journal:  Ann Oncol       Date:  2017-10-01       Impact factor: 32.976

8.  CD117-positive cells of the heart: progenitor cells or mast cells?

Authors:  Yan Zhou; Peng Pan; Lu Yao; Meng Su; Ping He; Na Niu; Michael A McNutt; Jiang Gu
Journal:  J Histochem Cytochem       Date:  2009-12-21       Impact factor: 2.479

9.  Mast cells and human hepatocellular carcinoma.

Authors:  Fabio Grizzi; Barbara Franceschini; Maurizio Chiriva-Internati; Young Liu; Paul L Hermonat; Nicola Dioguardi
Journal:  World J Gastroenterol       Date:  2003-07       Impact factor: 5.742

10.  Fas ligand (FasL, CD95L, APO-1L) expression in murine mast cells.

Authors:  A L Wagelie-Steffen; K Hartmann; H Vliagoftis; D D Metcalfe
Journal:  Immunology       Date:  1998-08       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.